GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akebia Therapeutics Inc (NAS:AKBA) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)

Akebia Therapeutics (Akebia Therapeutics) Total Revenue Growth Rate (Future 3Y To 5Y Est) : 6.85 (As of May. 03, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Akebia Therapeutics Total Revenue Growth Rate (Future 3Y To 5Y Est)?

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Akebia Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est) is 6.85.

Competitive Comparison of Akebia Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est)

For the Biotechnology subindustry, Akebia Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akebia Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akebia Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:

* The bar in red indicates where Akebia Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.


Akebia Therapeutics  (NAS:AKBA) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.

Akebia Therapeutics Total Revenue Growth Rate (Future 3Y To 5Y Est) Related Terms

Thank you for viewing the detailed overview of Akebia Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.

Akebia Therapeutics (Akebia Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akebia Therapeutics Inc (NAS:AKBA) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)
Comparable Companies
ALLK STOK APLT VSTM ZVRA STRO IKNA GLUE OBIO QSI OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
AX9:Germany AX9:Germany
Address
245 First Street, Cambridge, MA, USA, 02142
Website
https://www.akebia.com
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.
Executives
Ellen Snow officer: SVP, CFO and Treasurer C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Michel Dahan officer: SVP, Chief Business Officer C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Nicole R. Hadas officer: SVP, General Counsel, Sec. 20 PILGRAM DRIVE, WINCHESTER MA 01890
David A Spellman officer: SVP, CFO and Treasurer 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Steven Keith Burke officer: SVP, Chief Medical Officer 82 WILLIS ROAD, SUDBURY MA 01776
John P. Butler director, officer: CEO & President C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421
Violetta Cotreau officer: SVP, Chief Accounting Officer 245 FIRST STREET, 14TH FLOOR, CAMBRIDGE MA 02142
Ron Frieson director 245 FIRST STREET, 14TH FLOOR, CAMBRIDGE MA 02142
Dell Faulkingham officer: CCO C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
Leanne M Zumwalt director C/O THE ADVISORY BOARD CO WATERGATGE, 600 NEW HAMPSHIRE AVE NW, WASHINGTON DC 20037
Maxine Gowen director
Cynthia Smith director 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Myles Wolf director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
Karen L Tubridy officer: SVP, Chief Development Officer ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142